Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab Plus Cemiplimab in First-Line R/M HNSCC
NCT06769698Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Jun 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 6
01
Overview
A Phase 2 trial of fianlimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Regeneron Pharmaceuticals. Started Apr 2026; status: recruiting.
02
Drugs
fianlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06769698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769698.